Global peptic ulcer market forecast to reach $1.05 billion by 2018; FDA warns on PPIs

The global peptic ulcer therapeutics market was worth $892.4 million in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 2% to $1,046.2 million by 2018 by GlobalData, just as the US Food and Drug Administration issued a warning these drugs.

Peptic ulcers develop due to two main factors: infection with Helicobacter pylori and the long-term use of non-steroidal anti-inflammatory Drugs (NSAIDs). H. pylori infection accounts for almost 85% of all peptic ulcer cases. The peptic ulcer market is well served by proton pump inhibitors (PPIs), and include omeprazole, lansoprazole, pantoprazole, AstraZeneca’s Nexium (esomeprazole) and Eisai’s Aciphex (rabeprazole); and histamine blockers such as ranitidine, nizatidine, famotidine and cimetidine.

Omeprazole most prescribed drug